AALL1131; A Phase 3 Randomized Trial for HR B-ALL with Dasatinib Arm in Ph-like TKI Sensitive Mutations



Subscribe to be notified of changes or updates to this page.

The study compares 2 different experimental chemotherapy combinations with the usual chemotherapy combination given during post-Induction therapy. The 3 treatment plans we will be using include: a) therapy containing the usual/standard drugs - Control Arm or, b) therapy containing cyclophosphamide and etoposide- Experimental Arm 1 or, c) therapy containing clofarabine, cyclophosphamide and etoposide – Experimental Arm 2.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at pecheraJ [at] chop.edu or 267-425-3136.

Eligibility & Criteria

IRB #:
Official Title:
AALL1131; A Phase III Randomized Trial for Newly Diagnosed High Risk B- Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Study Phase:
Phase III
Eligible Age Range:
0 - 99 Years
Study Categories: